FCM
IOVA icon

Fieldview Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Fieldview Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-74,425
Closed -$551K – 496
2024
Q4 		$551K Buy
+74,425
New +$690K 0.09% 270

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fieldview Capital Management's IOVA Position: Q1 2025 in Review

Fieldview Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 74,425 shares — an estimated $551K sold.

Fieldview Capital Management first reported a position in IOVA in Q4 2024 and held it in 1 quarter. The position peaked at $551K in Q4 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Fieldview Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Fieldview Capital Management sold 74,425 Iovance Biotherapeutics shares in Q1 2025, an estimated $551K.
  • Fieldview Capital Management first reported a position in Iovance Biotherapeutics in Q4 2024 and held it in 1 quarter.
  • Fieldview Capital Management's Iovance Biotherapeutics position peaked at $551K in Q4 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Fieldview Capital Management's 13F filing for Q1 2025, filed 15 May 2025.